XLON
SYNC
Market cap703mUSD
Apr 02, Last price
87.80GBP
1D
0.23%
1Q
-15.09%
Jan 2017
-34.84%
IPO
-14.76%
Name
Syncona Ltd
Chart & Performance
P/E
14,281.31
P/S
1,759.33
EPS
0.01
Div Yield, %
—
Shrs. gr., 5y
-0.12%
Rev. gr., 5y
-41.24%
Revenues
31m
P
Net income
4m
P
CFO
20m
P
Dividend
Jun 20, 20190.023 GBP/sh
Earnings
Jun 18, 2025
Profile
Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | |
| Income | |||||||||
Revenues | 30,749 -177.28% | (39,791) -312.87% | |||||||
Cost of revenue | 39,253 | 15,000 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (8,504) | (54,791) | |||||||
NOPBT Margin | 137.70% | ||||||||
Operating Taxes | (4,634) | ||||||||
Tax Rate | |||||||||
NOPAT | (8,504) | (50,157) | |||||||
Net income | 3,788 -106.76% | (56,018) -733.83% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (20,223) | ||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 2,861 | 13,757 | |||||||
Net debt | (1,241,959) | (1,258,269) | |||||||
| Cash flow | |||||||||
Cash from operating activities | 20,473 | (265) | |||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | (20,223) | ||||||||
FCF | (21,245) | (51,486) | |||||||
| Balance | |||||||||
Cash | 261 | 11 | |||||||
Long term investments | 1,241,698 | 1,258,258 | |||||||
Excess cash | 1,240,422 | 1,260,259 | |||||||
Stockholders' equity | 1,259,101 | 1,254,655 | |||||||
Invested Capital | 10,675 | ||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 666,854 | 668,575 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (8,504) | (54,791) | |||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||